---
title: "Giant Biogene Holding Insider Ups Holding During Year"
description: "Giant Biogene Holding Co., Ltd. (HKG:2367) saw net insider buying over the past year, with Chief Scientific Officer Daidi Fan being the largest buyer, purchasing HK$2.5 billion worth of shares. Despit"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/273777469.md"
published_at: "2026-01-27T02:43:50.000Z"
---

# Giant Biogene Holding Insider Ups Holding During Year

> Giant Biogene Holding Co., Ltd. (HKG:2367) saw net insider buying over the past year, with Chief Scientific Officer Daidi Fan being the largest buyer, purchasing HK$2.5 billion worth of shares. Despite a significant sale of HK$2.3 billion by Fan, it occurred above the current share price of HK$33.84. Insiders own 55% of the company, valued at approximately HK$20 billion, indicating alignment with shareholders. While no transactions occurred in the last three months, the overall insider activity suggests optimism for the company's future.

Viewing insider transactions for **Giant Biogene Holding Co., Ltd.'s** (HKG:2367 ) over the last year, we see that insiders were net buyers. This means that a larger number of shares were purchased by insiders in relation to shares sold.

While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

## The Last 12 Months Of Insider Transactions At Giant Biogene Holding

In the last twelve months, the biggest single sale by an insider was when the Chief Scientific Officer, Daidi Fan, sold HK$2.3b worth of shares at a price of HK$66.65 per share. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The silver lining is that this sell-down took place above the latest price (HK$33.84). So it may not tell us anything about how insiders feel about the current share price. The only individual insider seller over the last year was Daidi Fan. Notably Daidi Fan was also the biggest buyer, having purchased HK$2.5b worth of shares.

Daidi Fan bought 39.23m shares over the last 12 months at an average price of HK$64.57. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

See our latest analysis for Giant Biogene Holding

Giant Biogene Holding is not the only stock insiders are buying. So take a peek at this **free** list of under-the-radar companies with insider buying.

## Does Giant Biogene Holding Boast High Insider Ownership?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. Giant Biogene Holding insiders own 55% of the company, currently worth about HK$20b based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.

## What Might The Insider Transactions At Giant Biogene Holding Tell Us?

There haven't been any insider transactions in the last three months -- that doesn't mean much. However, our analysis of transactions over the last year is heartening. It would be great to see more insider buying, but overall it seems like Giant Biogene Holding insiders are reasonably well aligned (owning significant chunk of the company's shares) and optimistic for the future. Of course, **the future is what matters most**. So if you are interested in Giant Biogene Holding, you should check out this **free** report on analyst forecasts for the company.

But note: **Giant Biogene Holding may not be the best stock to buy**. So take a peek at this **free** list of interesting companies with high ROE and low debt.

*For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.*

### Related Stocks

- [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md)
- [159849.CN - China Merchants CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159849.CN.md)
- [02367.HK - GIANT BIOGENE](https://longbridge.com/en/quote/02367.HK.md)
- [516930.CN - Minsheng Royal CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516930.CN.md)
- [516500.CN - ChinaAMC CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516500.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 早盘趋势｜巨子生物多头信心松动，关键支撑岌岌可危？ | 1 月 27 日，巨子生物（2367.HK）盘中弱势震荡，盘面反复探底，多次试探 28 元整数关口支撑未果。全天资金持续流出，绿盘成交占比高，显示多头信心逐步松动，主力持仓筹码开始松懈。 生物科技板块过去一周受地方政策分歧影响，持续表现低迷 | [Link](https://longbridge.com/en/news/273815223.md) |
| 3.5 亿首付款、总额达 85 亿美元！信达生物与礼来合作布局肿瘤免疫新药研发 | 信达生物与礼来达成突破性合作，将联合开发肿瘤及免疫新药。此次交易预付款 3.5 亿美元，总额最高达 85 亿美元。双方摒弃传统授权，采用从零开始的共同研发模式，标志着中国药企创新力获全球顶尖药企深度认可，开启全球战略协作新篇章。 | [Link](https://longbridge.com/en/news/275269682.md) |
| Gladstone Commercial-优先股 E｜8-K：2025 财年 Q4 营收 43.46 百万美元 |  | [Link](https://longbridge.com/en/news/276270574.md) |
| 美达生物将注销价值 27 亿韩元的自有股份 | Metabiomed Co Ltd :METABIOMED: 将取消价值 27 亿韩元的自有股份 | [Link](https://longbridge.com/en/news/276408478.md) |
| 埃隆·马斯克的 Neuralink 在中国激发了脑机接口技术的竞赛 | Neuralink，由埃隆·马斯克创立，正在推动中国脑机接口（BCI）发展的热潮，像 NeuroXess 这样的初创公司迅速进入人体试验阶段。NeuroXess 于 2021 年成立，已经在患者身上测试植入物。中国政府已将 BCI 列为战略 | [Link](https://longbridge.com/en/news/276460367.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
